

Ministry of Health

OHIP, Pharmaceuticals and Devices Division

Drug Submission Status

Report for December 2021

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
AA Pharma Inc.	AA-Telmisartan-Amlodipine	Twynsta	TELMISARTAN & AMLODIPINE BESYLATE	80 mg & 5 mg	tablet	02473488
AA Pharma Inc.	AA-Telmisartan-Amlodipine	Twynsta	TELMISARTAN & AMLODIPINE BESYLATE	80 mg & 10 mg	tablet	02473496
Accel Pharma	Accel-Entecavir	Baraclude	ENTECAVIR	0.5mg	tablet	02479907
Pharmaris Canada Inc.	PRZ-Rosuvastatin	Crestor	ROSUVASTATIN CALCIUM	5 mg	tablet	02505576
Pharmaris Canada Inc.	PRZ-Rosuvastatin	Crestor	ROSUVASTATIN CALCIUM	10 mg	tablet	02505584
Pharmaris Canada Inc.	PRZ-Rosuvastatin	Crestor	ROSUVASTATIN CALCIUM	20 mg	tablet	02505592

Pharmaris Canada Inc.	PRZ- Rosuvastatin	Crestor	ROSUVASTATIN CALCIUM	40 mg	tablet	02505606
Mantra Pharma Inc	M-Latanoprost- Timolol	Xalacom	LATANOPROST & TIMOLOL MALEATE	50 mcg/mL & 5 mg/mL	ophthalmic solution	02514516
Teligent Canada Inc.	Brimonidine Tartrate Ophthalmic Solution	Alphagan	BRIMONIDINE TARTRATE	0.2 % w/v	ophthalmic solution	02515377
Pharmascience Inc	Pmsc-Celecoxib	Celebrex	CELECOXIB	100 mg	capsule	02517116